The Food and Drug Administration (FDA) won’t publish its safety review of the abortion drug mifepristone until March, it disclosed in a Wednesday court filing, adding that it won’t impose any new restrictions on the pill before that point. The revelations are likely to further anger anti-abortion activists, who have been losing patience with the...
The Food and Drug Administration (FDA) won’t publish its safety review of the abortion drug mifepristone until March, it disclosed in a Wednesday court filing, adding that it won’t impose any new restrictions on the pill before that point. The revelations are likely to further anger anti-abortion activists, who have been losing patience with the...
<iframe src="https://statesidedaily.com/embed/cluster/b05131761e060736f7ca531288e5fbef5a58a228" width="100%" height="320" style="border:0;max-width:680px" loading="lazy" title="FDA: Mifepristone review won't be done until March"></iframe>
